Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC

NCT06064279 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

FED

Sponsor class

Stopped The funding for this trial was removed.

Conditions

Stage IV NSCLC

Interventions

DRUG: Poly ICLC
DRUG: IVIG

Sponsor

VA Office of Research and Development

Collaborators

[object Object]